ReviewGynecologic oncology2010
Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.
Review in Gynecologic oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- LAMC3 interference reduces drug resistance of carboplatin-resistant ovarian cancer cells.Scientific reports · 2025Article
- Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.Journal of gynecologic oncology · 2021Article
- The Role of Endoglin in Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.RNA biology · 2020Review
- Prediction of the treatment response in ovarian cancer: a ctDNA approach.Journal of ovarian research · 2020Review
- Association between G-protein coupled receptor 4 expression and microvessel density, clinicopathological characteristics and survival in hepatocellular carcinoma.Oncology letters · 2020Article
- Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer.Cancer management and research · 2019Article
- microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.Oncotarget · 2017Article
- Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer.Cancer science · 2015Article
- Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Expression and biological role of cytoglobin in human ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14.Oncotarget · 2014Article
- New developments in the treatment of ovarian cancer--future perspectives.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Review
- DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.The pharmacogenomics journal · 2013Article
- CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Expression and biological role of δ-catenin in human ovarian cancer.Journal of cancer research and clinical oncology · 2012Article
- Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.BMC cancer · 2012Article
- Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.Gynecologic oncology · 2012Article
- Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo review the translational research (TR) performed in the Gynecologic Oncology Group (GOG) to evaluate ovarian cancer markers, profiles and novel therapies.
methodsProspective trials with stand alone or embedded TR objectives involving patient and specimen accrual as well as retrospective studies using banked specimens and resources were and continue to be performed in the GOG. Appropriate statistical methods are employed to evaluate associations with clinical characteristics and outcomes including tumor response, adverse events, progression free survival and overall survival.
resultsHighlights are presented for some of the collaborative and multidisciplinary TR conducted with the GOG to evaluate markers, pathway and novel therapeutics in epithelial ovarian, primary peritoneal and/or fallopian tube cancer. For example, in GOG 111, high immunohistochemical (IHC) expression of cyclin E was associated with a shorter median survival (29 versus 35 months) and an increased risk of death (hazard ratio [HR]=1.4, 95% confidence interval [CI]=1.0-2.1, p=0.05). In GOG 114/132, non-detectable immunoblot expression of maspin was associated with debulking status (p=0.034) and an increased risk of disease progression (HR=1.89, 95% CI=1.04-3.45, p=0.038) and death (HR=1.99, 95% CI=1.07-3.69, p=0.030) while high CD105-microvessel density (MVD), but not CD31-MVD in tumor was associated with increased risk of disease progression (HR=1.873, 95% CI=1.102-3.184, p=0.020) but not death. In GOG 172, low IHC expression of BRCA1 was associated with advanced stage (p<0.001), serous histology (p<0.001) and a reduced risk of disease progression (HR=0.64, 95% CI=0.42-0.96) and death (HR=0.51, 95% CI=0.32-0.83) while the CA/AA versus CC genotypes in C8092A in ERCC1 were associated with an increased risk of disease progression (HR=1.44, 95% CI=1.06-1.94, p=0.018) and death (HR=1.50, 95% CI=1.07-2.09, p=0.018).
conclusionsThe GOG has an extensive TR program that provides clues regarding the molecular and biochemical mechanisms of disease, treatments and outcomes in women with or at risk for a gynecologic malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.